Search - tctmd.com

Displaying 481 - 500 of 545

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

Shelley Wood

November 30, 2016

News Conference News AHA 2016

Stark Mortality Differences Seen in GARY Registry Tracking TAVR and Surgical Replacement

Shelley Wood

November 14, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Industry News

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

November 02, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

Presentation TCT 2016

Debate: Is Left Atrial Appendage Closure Underutilized? Yes, It Should Be Offered to All Patients With Atrial Fibrillation (I Would Want It!)

Presenter: Andreas Baumbach, David Hildick-Smith, Ted Feldman

November 01, 2016

Presentation TCT 2016

TCT 25: Efficacy and Safety of Left Atrial Appendage Closure vs Medical Treatment in Atrial Fibrillation: A Network Meta-Analysis From Randomized Trials

Presenter: Zahid Amin, Jacqueline Saw, Luis Nombela-Franco

October 31, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, David Hildick-Smith

October 30, 2016

Presentation TCT 2016

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog

October 30, 2016

Presentation TCT 2016

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Jean-Claude Laborde, Azfar G. Zaman

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2016

Stark Mortality Differences Seen in GARY Registry Tracking TAVR and Surgical Replacement

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Initial Results of LAA Closure Device for Stroke Prevention in Patients with Atrial Fibrillation Demonstrate Device Safety and Low Rates of Major Adverse Events

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Debate: Is Left Atrial Appendage Closure Underutilized? Yes, It Should Be Offered to All Patients With Atrial Fibrillation (I Would Want It!)

TCT 25: Efficacy and Safety of Left Atrial Appendage Closure vs Medical Treatment in Atrial Fibrillation: A Network Meta-Analysis From Randomized Trials

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Debate #1: Should Low bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? Yes As Long As Full Consent Is Provided, Let the Patient Decide!

Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First

TCT 648: Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content